GlassScriptPhysician profile
Robert Santiago
NPI 1720121213
$10,557.80
in general payments reported to CMS, 2019-2025
39 companies · $717 in 2025
The $717 reported for 2025 was more than what 89% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $1,499 · 2021: $1,923 · 2022: $1,669 · 2023: $999 · 2024: $1,591 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,179.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,957.08 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $450.18 | 2019-2025 | Jardiance, Emgality |
| Esperion Therapeutics, INC. | $442.58 | 2020-2024 | Nexletol, Nexlizet |
| Astellas Pharma US INC | $441.70 | 2019-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $404.55 | 2019-2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $363.87 | 2019-2022 | |
| Novo Nordisk INC | $359.72 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $343.42 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.73 | 2019-2024 | Jardiance, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $225.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $216.23 | 2019-2022 | |
| Pfizer INC. | $202.28 | 2019-2024 | |
| Amarin Pharma, INC. | $197.92 | 2019-2021 | |
| Amgen INC. | $165.67 | 2019-2024 | Repatha |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Santiago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.